Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Bioorg Med Chem Lett. 2012 May 1;22(9):3349-53. doi: 10.1016/j.bmcl.2012.02.107. Epub 2012 Mar 14.

Substituted aminopyrimidine protein kinase B (PknB) inhibitors show activity against Mycobacterium tuberculosis.

Author information

  • 1Centre for Therapeutics Discovery, MRC Technology, 1-3 Burtonhole Lane, Mill Hill, London NW7 1AD, UK. tim.chapman@tech.mrc.ac.uk

Abstract

A high-throughput screen against PknB, an essential serine-threonine protein kinase present in Mycobacterium tuberculosis (M. tuberculosis), allowed the identification of an aminoquinazoline inhibitor which was used as a starting point for SAR investigations. Although a significant improvement in enzyme affinity was achieved, the aminoquinazolines showed little or no cellular activity against M. tuberculosis. However, switching to an aminopyrimidine core scaffold and the introduction of a basic amine side chain afforded compounds with nanomolar enzyme binding affinity and micromolar minimum inhibitory concentrations against M. tuberculosis. Replacement of the pyrazole head group with pyridine then allowed equipotent compounds with improved selectivity against a human kinase panel to be obtained.

Copyright © 2012 Elsevier Ltd. All rights reserved.

PMID:
22469702
[PubMed - indexed for MEDLINE]
PMCID:
PMC3368261
Free PMC Article

Images from this publication.See all images (9)Free text

Figure 2
Figure 3
Scheme 1
Scheme 2
Scheme 3
Scheme 4
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk